What is Leerink Partnrs’ Estimate for BBIO FY2028 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at Leerink Partnrs lowered their FY2028 earnings estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn $4.31 per share for the year, down from their previous forecast of $4.38. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.59) per share.

A number of other research analysts have also weighed in on the stock. Bank of America reaffirmed a “buy” rating and issued a $42.00 price target on shares of BridgeBio Pharma in a research note on Wednesday, September 11th. Evercore ISI decreased their price target on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Oppenheimer began coverage on shares of BridgeBio Pharma in a research note on Thursday, October 3rd. They issued a “market perform” rating on the stock. Leerink Partners decreased their price target on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. cut their price objective on shares of BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.50.

BridgeBio Pharma Trading Down 2.7 %

Shares of BridgeBio Pharma stock opened at $24.11 on Thursday. The firm has a market capitalization of $4.53 billion, a PE ratio of -10.00 and a beta of 1.09. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $44.32. The firm’s 50-day moving average price is $25.78 and its 200 day moving average price is $26.44.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. Bfsg LLC boosted its position in shares of BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after purchasing an additional 790 shares during the period. Headlands Technologies LLC purchased a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $48,000. Values First Advisors Inc. purchased a new position in shares of BridgeBio Pharma during the 3rd quarter worth approximately $57,000. CWM LLC boosted its position in shares of BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after purchasing an additional 1,964 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of BridgeBio Pharma during the 1st quarter worth approximately $117,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 27,389 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $676,234.41. Following the completion of the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at $120,917,867.67. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brian C. Stephenson sold 4,155 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $102,586.95. Following the sale, the chief financial officer now owns 85,192 shares of the company’s stock, valued at $2,103,390.48. This represents a 4.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,831,544 shares of company stock worth $150,128,821 in the last 90 days. Insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.